For the Inventor, By the Inventor

Enter assignee name

Anormed, Inc.

USPTO Granted Patents = 40

CIPO Patents = 5

EPO Patents = 2

Forward Citations = 745

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Gary James Bridger (23 out of 45 patents)

Renato Skerlj (19 out of 33 patents)

Dominique Schols (16 out of 31 patents)

4. David Earl Bogucki (15 out of 32 patents)

5. Ernest John McEachern (13 out of 43 patents)

6. Trevor R Wilson (11 out of 16 patents)

7. Jason B Crawford (11 out of 18 patents)

8. Curtis Harwig (10 out of 32 patents)

9. Yuanxi Zhou (10 out of 40 patents)

10. Al Kaller (10 out of 18 patents)

11. Siqiao Nan (10 out of 16 patents)

12. Bem Atsma (8 out of 12 patents)

13. Michael J Abrams (7 out of 31 patents)

14. Christopher Dennis Smith (5 out of 9 patents)

15. Eva Maria Boehringer (5 out of 7 patents)

Core Competencies:

Amino-Substituted Bicyclic Rings

Chemokine Receptor Binding

CXCR4 Antagonist

Progenitor Cell Mobilization

Antitumor Agents

Antiviral Compounds

White Blood Cell Enhancement

Platinum Complexes

Immunosuppressive Compositions

Cytokine Inhibitors

Pharmaceutical Compositions

Substituted Azaspiranes

40 patents: Sort by Forward Citations

1. 7452994 - Synthesis of enantiomerically pure amino-substituted fused bicyclic rings (2008-11-18),

2. 7354934 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy (2008-04-08),

3. 7354932 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy (2008-04-08),

4. 7332605 - Process for the synthesis of CXCR4 antagonist (2008-02-19),

5. 7312234 - Chemokine receptor binding heterocyclic compounds (2007-12-25),

6. 7183273 - Chemokine receptor binding heterocyclic compounds (2007-02-27),

7. 7169750 - Methods to mobilize progenitor/stem cells (2007-01-30),

8. 7160872 - Methods to treat conditions mediated by chemokine receptors (2007-01-09),

9. 7135570 - Synthesis of enantiomerically pure amino-substituted fused bicyclic rings (2006-11-14),

10. 7091217 - Chemokine receptor binding heterocyclic compounds (2006-08-15),

11. 7084155 - Chemokine receptor binding heterocyclic compounds (2006-08-01),

12. 7022717 - Chemokine receptor binding heterocyclic compounds (2006-04-04),

13. 6987102 - Methods to mobilize progenitor/stem cells (2006-01-17),

14. 6894049 - Platinum complexes as antitumor agents (2005-05-17),

15. 6872714 - Methods to modulate conditions mediated by the CXCR4 receptor (2005-03-29),

Anormed, Inc. is a biopharmaceutical company that specializes in the research, development, and commercialization of novel therapeutics. With a focus on improving patient outcomes, Anormed aims to address unmet medical needs in areas such as oncology, immunology, and neurology. Through its innovative drug discovery platform and collaborative partnerships with leading academic institutions and pharmaceutical companies, Anormed is dedicated to advancing healthcare through the development of groundbreaking treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

40 Patents

#38 in

#327 in Canada

#16,570 in the World

Anormed, Inc.

Forward Citations = 745

50 inventors:

Gary James Bridger (23 out of 45 patents)

Renato Skerlj (19 out of 33 patents)

Dominique Schols (16 out of 31 patents)

4. David Earl Bogucki (15 out of 32 patents)

5. Ernest John McEachern (13 out of 43 patents)

Please report any incorrect information to support@idiyas.com

Loading…